Fecal miRNA profiles in colorectal cancers with mucinous morphology.

Stool miRNA signatures colorectal cancer mucinous morphology tumor heterogeneity

Journal

Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812

Informations de publication

Date de publication:
06 Jun 2024
Historique:
received: 19 02 2024
medline: 6 6 2024
pubmed: 6 6 2024
entrez: 6 6 2024
Statut: aheadofprint

Résumé

Diagnostic performance of molecular markers in surrogate tissues like stool may be affected by colorectal cancer (CRC) morphological heterogeneity. The mucinous histotype represents a subgroup of CRC with a peculiar molecular program and unfavorable disease progression. However, the percentage of mucinous morphology necessary to define this subtype is still a matter of debate. In this study, we investigated whether stool miRNA profiles of CRC patients differ in patients with mucinous histopathological subtypes compared to non-mucinous cancers. In this respect, we also explored how the stool miRNA signature reported in our previous multicentric study (Pardini et al., Gastroenterology 2023) behave in this histotype. Small-RNA sequencing was performed in fecal and tissue samples of an Italian cohort (n=172), including 27 CRC with mucinous morphology (mucinous cancers with >50% mucinous morphology and those with mucinous component >5% but <50%), 58 non-mucinous CRC, and 87 colonoscopy-negative controls. Results were compared with fecal miRNA profiles of a cohort from the Czech Republic (n=98). Most of the differentially expressed (DE) stool miRNAs (n=324) were in common between CRC with mucinous morphology and non-mucinous histopathological subtypes in comparison with healthy controls. Interestingly, the altered levels of 25 fecal miRNAs previously identified distinguishing CRC cases from controls in both cohorts were also confirmed after stratification for mucinous morphology. Forty-nine miRNAs were DE exclusively in CRC with mucinous morphology and 61 in non-mucinous CRC. Mucinous cancers and those with mucinous component showed fairly similar profiles that were comparable in the Czech cohort. Among the stool DE miRNAs observed in CRC with mucinous morphology, 20 were also altered in the comparison between tumor and adjacent mucosa tissue. This study highlights miRNAs specifically altered in CRC with mucinous morphology. Nevertheless, the performance of our stool miRNA signature in accurately distinguishing CRC cases from controls was not significantly affected by this histological subtype. This aspect further supports the use of stool miRNAs for noninvasive diagnosis and screening strategies.

Identifiants

pubmed: 38843106
pii: 7689086
doi: 10.1093/mutage/geae015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Alessio Naccarati (A)

Italian Institute for Genomic Medicine (IIGM), c/o IRCCS Candiolo, Candiolo 10060, Turin, Italy.
Candiolo Cancer Institute, FPO IRCCS, Candiolo 10060, Turin, Italy.

Mihnea P Dragomir (MP)

Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin 10117, Germany.
German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
Berlin Institute of Health at Charit´e - Universit¨atsmedizin Berlin, Charit´eplatz 1, 10117 Berlin, Germany.

Sonia Tarallo (S)

Italian Institute for Genomic Medicine (IIGM), c/o IRCCS Candiolo, Candiolo 10060, Turin, Italy.
Candiolo Cancer Institute, FPO IRCCS, Candiolo 10060, Turin, Italy.

Amedeo Gagliardi (A)

Italian Institute for Genomic Medicine (IIGM), c/o IRCCS Candiolo, Candiolo 10060, Turin, Italy.
Candiolo Cancer Institute, FPO IRCCS, Candiolo 10060, Turin, Italy.

Virginia Alberini (V)

Italian Institute for Genomic Medicine (IIGM), c/o IRCCS Candiolo, Candiolo 10060, Turin, Italy.
Candiolo Cancer Institute, FPO IRCCS, Candiolo 10060, Turin, Italy.
Department of Clinical and Biological Sciences, University of Torino, Turin 10100, Italy.

Tomas Buchler (T)

Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague 150 06, Czech Republic.

Vaclav Liska (V)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen 32300, Czech Republic.
Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen 32300, Czech Republic.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague 14220, Czech Republic.

Gaetano Gallo (G)

Department of Surgery, "La Sapienza" University of Rome, Rome 00161, Italy.
Department of Colorectal Surgery, Clinica S. Rita, Vercelli 13100, Italy.

Veronika Vymetalkova (V)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague 14220, Czech Republic.

Ludmila Vodickova (L)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen 32300, Czech Republic.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague 14220, Czech Republic.
Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague 12800, Czech Republic.

Pavel Vodicka (P)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen 32300, Czech Republic.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague 14220, Czech Republic.
Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague 12800, Czech Republic.

Barbara Pardini (B)

Italian Institute for Genomic Medicine (IIGM), c/o IRCCS Candiolo, Candiolo 10060, Turin, Italy.
Candiolo Cancer Institute, FPO IRCCS, Candiolo 10060, Turin, Italy.

Giulio Ferrero (G)

Department of Clinical and Biological Sciences, University of Torino, Turin 10100, Italy.
Italian Institute for Genomic Medicine (IIGM), c/o IRCCS Candiolo, Candiolo 10060, Turin, Italy.

Classifications MeSH